Literature DB >> 15916491

Review: mixing new cocktails: drug interactions in antiretroviral regimens.

Benjamin Young1.   

Abstract

Current highly active antiretroviral therapy (HAART) for the treatment of HIV infection requires the concomitant administration of three or four different agents, often with a high potential for drug-drug interactions. Additionally, some HIV-positive patients still require concomitant treatment with drugs for opportunistic infections, some require medication to treat unrelated medical conditions and/or the metabolic complications of antiretroviral therapy, others may self-medicate with herbal formulations and/or over-the-counter drugs, and still others many take drugs for recreational reasons or to manage addiction. Therefore, the virtually limitless number of drug combinations that may be taken by patients undergoing treatment of HIV infection makes drug-drug interactions almost inevitable. Managing these interactions is one of the major challenges associated with the multidrug regimens used for HIV therapy. This paper provides an overview of the most common interactions between antiretrovirals in the same and different classes-nucleoside analogue reverse transcriptase inhibitors (NRTI), protease inhibitors (PI), and non-nucleoside reverse transcriptase inhibitors (NNRTI)-by focusing on principles rather than specific interactions. The paper also addresses interactions between these antiretrovirals and other commonly used medications that may be prescribed concomitantly.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15916491     DOI: 10.1089/apc.2005.19.286

Source DB:  PubMed          Journal:  AIDS Patient Care STDS        ISSN: 1087-2914            Impact factor:   5.078


  8 in total

1.  Lipid lowering effects of Momordica charantia (Bitter Melon) in HIV-1-protease inhibitor-treated human hepatoma cells, HepG2.

Authors:  Pratibha V Nerurkar; Yun Kyung Lee; Ellen H Linden; Steven Lim; Laurel Pearson; Jennifer Frank; Vivek R Nerurkar
Journal:  Br J Pharmacol       Date:  2006-07-03       Impact factor: 8.739

2.  Raltegravir: The evidence of its therapeutic value in HIV-1 infection.

Authors:  Kavya Ramkumar; Nouri Neamati
Journal:  Core Evid       Date:  2010-06-15

3.  Multi-level analysis of organic anion transporters 1, 3, and 6 reveals major differences in structural determinants of antiviral discrimination.

Authors:  David M Truong; Gregory Kaler; Akash Khandelwal; Peter W Swaan; Sanjay K Nigam
Journal:  J Biol Chem       Date:  2008-01-03       Impact factor: 5.157

4.  Prevalence of potential drug-drug interactions involving antiretroviral drugs in a large Kenyan cohort.

Authors:  Gabriel Kigen; Sylvester Kimaiyo; Winstone Nyandiko; Brian Faragher; Edwin Sang; Beatrice Jakait; Andrew Owen; David Back; Sara Gibbons; Kay Seden; Saye H Khoo
Journal:  PLoS One       Date:  2011-02-23       Impact factor: 3.240

5.  Plasma concentrations of efavirenz and nevirapine among HIV-infected patients with immunological failure attending a tertiary hospital in North-western Tanzania.

Authors:  Daniel W Gunda; Christa Kasang; Benson R Kidenya; Rodrick Kabangila; Stephen E Mshana; Jeremiah Kidola; Samuel E Kalluvya; Gilbert W Kongola; Hartwig Klinker
Journal:  PLoS One       Date:  2013-09-10       Impact factor: 3.240

6.  Drug-transporter mediated interactions between anthelminthic and antiretroviral drugs across the Caco-2 cell monolayers.

Authors:  Gabriel Kigen; Geoffrey Edwards
Journal:  BMC Pharmacol Toxicol       Date:  2017-05-04       Impact factor: 2.483

7.  Potential drug-drug interactions in HIV-infected children on antiretroviral therapy in Lagos, Nigeria.

Authors:  Kazeem A Oshikoya; Ibrahim A Oreagba; Saheed Lawal; Olufunsho Awodele; Olayinka O Ogunleye; Idowu O Senbanjo; Sunday O Olayemi; Veronica C Ezeaka; Edamisan O Temiye; Titilope A Adeyemo; Oluranti Opanuga; Olufunmilayo A Lesi; Sulaimon A Akanmu
Journal:  HIV AIDS (Auckl)       Date:  2014-04-05

8.  Intracellular accumulation of Praziquantel in T lymphoblastoid cell lines, CEM (parental) and CEMVBL(P-gp-overexpressing).

Authors:  Gabriel Kigen; Geoffrey Edwards
Journal:  BMC Pharmacol Toxicol       Date:  2016-08-14       Impact factor: 2.483

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.